In summary, our study shows that the combination of cetuximab with celecoxib enhances the anti-tumor efficacy of both drugs in CRC cells, and reduces CSC subpopulation, due to impairment of EGFR-RAS-FOXM1-β-catenin signaling axis. Here, EGFR is linked to colorectal carcinoma.